NCT04116320 - Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 21, 2019

Primary Completion Date

August 15, 2023

Study Completion Date

August 15, 2023

Conditions

MelanomaBreast CancerMerkel Cell CarcinomaSquamous Cell CancerNon Small Cell Lung CancerCervical CancerUrothelial CarcinomaOvarian CancerHepatocellular CarcinomaSmall-cell Lung CancerMicrosatellite Instability HighGastric CancerEsophageal Cancer

Interventions

DEVICE

Echopulse

The Echopulse device delivers focused ultrasound ablation (FUSA) therapy. FUSA is a technology that delivers continuous high-intensity focused ultrasound to ablate tissue.

DRUG

Poly ICLC

Poly-ICLC is a TLR3 agonist.

DRUG

Standard of Care PD-1 Therapy

PD-1 therapy FDA approved for use on a 3-week schedule will be used per standard of care.

Trial Locations (1)

22908

University of Virginia, Charlottesville